Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723
Groenwold R, Uddin M, Roes K, de Boer A, Rivero-Ferrer E, Martin E, Gatto N, Klungel O. Instrumental variable analysis in randomized trials with non-compliance and observational pharmacoepidemiologic studies. OA Epidemiology. 2014 May 9;2(1):9.
Khellaf M, Le Moine JG, Poitrinal P, Francesconi C, Haddad A, Bierling P, Michel M, Eckert L, Launois R, Godeau B. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol. 2011 Apr;90(4):441-6. doi: 10.1007/s00277-010-1087-x
Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.